PharmaVoice - Latest Newshttps://www.pharmavoice.com/news/News for pharmacy prosen-usFri, 14 Jun 2024 08:00:00 -0400Pfizer’s Paxlovid flunks long COVID study as researchers uncover the condition’s deep tollhttps://www.pharmavoice.com/news/pfizer-paxlovid-long-covid-study-trial/718910/<p>While researchers gain ground understanding long COVID&rsquo;s impact, viable treatments could still be a long way off.</p>Meagan ParrishFri, 14 Jun 2024 08:00:00 -0400https://www.pharmavoice.com/news/pfizer-paxlovid-long-covid-study-trial/718910/Regenxbio CEO to step down after 15 yearshttps://www.pharmavoice.com/news/regenxbio-kenneth-mills-ceo-curran-simpson/718835/<p>Kenneth Mills will become chair of the gene therapy developer&#39;s board while Curran Simpson, the current chief operating officer, will take his place as company head.</p>Ned PagliaruloThu, 13 Jun 2024 12:00:00 -0400https://www.pharmavoice.com/news/regenxbio-kenneth-mills-ceo-curran-simpson/718835/Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for nowhttps://www.pharmavoice.com/news/alzheimers-lilly-donanemab-leqembi-amyloid-tau-pipeline/718785/<p>Lilly is the latest to approach the coveted Alzheimer&rsquo;s approval, but a slate of drugmakers are lining up clinical trials in amyloid and tau to take a shot at improving patient outcomes.</p>Michael GibneyThu, 13 Jun 2024 08:00:00 -0400https://www.pharmavoice.com/news/alzheimers-lilly-donanemab-leqembi-amyloid-tau-pipeline/718785/Behind the powerful computations, AI’s role in pharma is still beset by challengeshttps://www.pharmavoice.com/news/ai-pharma-drug-challenges-panna-sharma/718666/<p>Small biotechs are saving time and money leveraging AI to develop new drugs, but incomplete data and disease complexity remain hurdles for the space.</p>Amy BaxterWed, 12 Jun 2024 08:00:00 -0400https://www.pharmavoice.com/news/ai-pharma-drug-challenges-panna-sharma/718666/Despite adcomm rejection, Lykos CEO sees future for MDMA drughttps://www.pharmavoice.com/news/adcomm-rejection-lykos-mdma-ptsd/718650/<p>Although the rebuff makes approval &ldquo;a bit more challenging,&rdquo; Lykos is moving forward with the psychedelic-based treatment for PTSD.</p>Alexandra PecciWed, 12 Jun 2024 08:00:00 -0400https://www.pharmavoice.com/news/adcomm-rejection-lykos-mdma-ptsd/718650/FDA’s platform designation aims to ease R&D pain pointshttps://www.pharmavoice.com/news/program-draft-guidance-drug-development/718522/<p>A new program creates approval pathways for multiple drugs developed on the same platform.&nbsp;</p>Amy BaxterTue, 11 Jun 2024 08:00:00 -0400https://www.pharmavoice.com/news/program-draft-guidance-drug-development/718522/As Big Pharma places bigger bets on ADCs, here’s where the field is headed nexthttps://www.pharmavoice.com/news/antibody-drug-adc-astrazeneca-abbvie-cancer/718521/<p>With more drugmakers getting into the antibody-drug conjugate game, emerging innovations signal a bright future for the technology.</p>Michael GibneyTue, 11 Jun 2024 08:00:00 -0400https://www.pharmavoice.com/news/antibody-drug-adc-astrazeneca-abbvie-cancer/718521/Behind Big Pharma’s layoffs — is there an end in sight?https://www.pharmavoice.com/news/big-pharma-layoffs-patent-cliffs-bms-takeda/718333/<p>A slew of major companies, including BMS, have announced cost-cutting measures in recent months. What will it take to turn the tide?</p>Kelly BilodeauMon, 10 Jun 2024 08:00:00 -0400https://www.pharmavoice.com/news/big-pharma-layoffs-patent-cliffs-bms-takeda/718333/Pharma’s R&D gamble: picking pipeline winners in a risky fieldhttps://www.pharmavoice.com/news/pharma-biotech-pipeline-genmab-jnj-patent-market/718247/<p>How leaders from biotech, Big Pharma and the investment world know when they&#39;ve found the right candidate or company to back.</p>Meagan ParrishFri, 07 Jun 2024 08:00:00 -0400https://www.pharmavoice.com/news/pharma-biotech-pipeline-genmab-jnj-patent-market/718247/A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myershttps://www.pharmavoice.com/news/cancer-drug-access-disparity-city-of-hope-bristol-myers-oncology/718133/<p>Cancer care is improving so quickly that receiving newer medications can be difficult &mdash; City of Hope&rsquo;s wide oncology network and a 10-year commitment from Bristol Myers Squibb offer some solutions.</p>Michael GibneyThu, 06 Jun 2024 08:00:00 -0400https://www.pharmavoice.com/news/cancer-drug-access-disparity-city-of-hope-bristol-myers-oncology/718133/